Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How sacituzumab govitecan and next-gen TROP2 ADCs are reshaping endometrial and urothelial cancer treatment — and what resistance mechanisms mean for the pipeline.
Article | Rapport How federated learning enables AI model training across distributed manufacturing sites without sharing raw data — architecture, privacy, and industrial deployment.
Article | Rapport Ifinatamab deruxtecan's DeLLphi-304 Phase III trial is redefining first-line small cell lung cancer treatment. Explore the science, patent landscape, and clinical implications.
Article | Rapport No verified patent or literature data was found for deterministic latency in industrial Ethernet for real-time robot control. Learn what this means for your research.
Article | Rapport Ulotaront, ralmitaront, and the TAAR1 agonist pipeline are reshaping schizophrenia and depression drug discovery. See the competitive landscape.
Article | Rapport Explore the key technical tradeoffs between hydrogen combustion and fuel cell powertrains for aviation — efficiency, weight, emissions, and integration challenges.
Article | Rapport Roche's trontinemab uses a transferrin receptor brain-shuttle to deliver amyloid-beta antibody at higher brain concentrations with a differentiated ARIA profile. Full Phase II analysis.
Article | Rapport How do model-based and data-driven fault detection methods compare for industrial rotating machinery? A technical guide for R&D and IP professionals.
Article | Rapport Oveporexton is the first orexin receptor agonist targeting narcolepsy type 1. Explore its FDA approval trajectory, mechanism, and competitive market dynamics.
Article | Rapport Key engineering challenges of building reliable humanoid robots for industrial deployment at scale — from actuator reliability to locomotion control and dexterity.
Article | Rapport Explore the key differences between physics-based and data-driven modeling for industrial process optimization, including hybrid approaches and when to use each.
Article | Rapport Tirzepatide's SURPASS-CVOT trial examines GLP-1/GIP dual agonist cardiovascular and renal outcomes in type 2 diabetes. Explore the science, IP landscape, and clinical significance.
Article | Rapport How do open-source and proprietary LLMs differ for enterprise R&D? Compare customisation, cost, compliance, and performance to make smarter AI deployment decisions.
Article | Rapport Sparsentan targets both ETA and AT1 receptors for FSGS and IgAN treatment. Explore the dual receptor antagonism mechanism, IP landscape, and clinical signals.
Article | Rapport IMerge Phase 3 trial: imetelstat achieved 39.8% 8-week transfusion independence vs 15% placebo in lower-risk MDS. Full pipeline analysis and biomarker data.